FDA Needs Better Postmarket Data, Not More Postmarket Authority – Schultz
This article was originally published in The Gray Sheet
Executive Summary
FDA should establish a permanent network of hospitals to collect device postmarket data while lowering the evidence standard for market approval, Harvard Clinical Research Institute Chief Scientific Officer Richard Kuntz, MD, suggests